Publications

  1. Shreders AJ, Niazi SK, Hodge DO, Chimato NT, Kureti M, Kirla N, Agrawal A, Swaika A, Gustetic E, Foster R, Nelson KA, Jani P, Chanan-Khan AA, Ailawadhi S. Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies. Ann Hematol. 2017 Dec 7 Epub 2017 Dec 07
    View PubMed
  2. Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. Am J Hematol. 2017 Dec; 92 (12):1362-1369 Epub 2017 Oct 19
    View PubMed
  3. Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017 Nov 30; 130 (22):2392-2400 Epub 2017 Aug 28
    View PubMed
  4. Ailawadhi S, Frank RD, Advani P, Swaika A, Temkit M, Menghani R, Sharma M, Meghji Z, Paulus S, Khera N, Hashmi SK, Paulus A, Kakar TS, Hodge DO, Colibaseanu DT, Vizzini MR, Roy V, Colon-Otero G, Chanan-Khan AA. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med. 2017 Nov 3 Epub 2017 Nov 03
    View PubMed
  5. Chanan-Khan AA, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, Kassis J, Simpson D, Zhang J, Purse B, Foa R. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2017 Nov; 4 (11):e534-e543 Epub 2017 Sept 25
    View PubMed
  6. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Nov; 15 (11):1414-1427
    View PubMed
  7. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06
    View PubMed
  8. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 01; 3 (9):1257-1265
    View PubMed
  9. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia. 2017 Sep 01 Epub 2017 Sept 01
    View PubMed
  10. Ailawadhi S, Bhatia K, Aulakh S, Meghji Z, Chanan-Khan A. Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet? Curr Hematol Malig Rep. 2017 Aug; 12 (4):309-316
    View PubMed
  11. Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017 Jul; 58: (7)1630-1639.
    View PubMed
  12. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017 Jun 29; 129 (26):3419-3427 Epub 2017 Apr 19
    View PubMed
  13. Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo GT, Smith MD, Leis J, Chanan-Khan A, Schwager SM, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma. 2017 Jun; 58 (6):1376-1383 Epub 2016 Nov 08
    View PubMed
  14. Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, Caulfield TR, Kuranz-Blake M, Chitta K, Wang X, Asmann Y, Hudec R, Springer W, Ailawadhi S, Chanan-Khan A. Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017 May 26; 7: (5)e565.
    View PubMed
  15. Chanan-Khan A, Egyed M, Robak T, Martinelli de Oliveira FA, Echeveste MA, Dolan S, Desjardins P, Blonski JZ, Mei J, Golany N, Zhang J, Gribben JG. Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia. 2017 May; 31: (5)1240-1243.
    View PubMed
  16. Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget. 2017 Apr 18; 8: (16)27145-27154.
    View PubMed
  17. Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenstrom's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan; 4: (1)e24-e34.
    View PubMed
  18. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016 Dec; 22 (12):1411-1420 Epub 2016 Nov 14
    View PubMed
  19. Paulus A, Akhtar S, Caulfield TR, Samuel K, Yousaf H, Bashir Y, Paulus SM, Tran D, Hudec R, Cogen D, Jiang J, Edenfield B, Novak A, Ansell SM, Witzig T, Martin P, Coleman M, Roy V, Ailawadhi S, Chitta K, Linder S, Chanan-Khan A. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood Cancer J. 2016 Nov 4; 6 (11):e492 Epub 2016 Nov 04
    View PubMed
  20. Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol. 2016 Sep; 3: (9)e407-14.
    View PubMed
  21. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25; 375 (8):754-66
    View PubMed
  22. Ailawadhi S, Paulus A, Chanan-Khan A. Preclinical models of Waldenstrom's macroglobulinemia and drug resistance. Best Pract Res Clin Haematol. 2016 Jun; 29 (2):169-178 Epub 2016 Sept 04
    View PubMed
  23. Paulus A, Ailawadhi S, Chanan-Khan A. Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Pract Res Clin Haematol. 2016 Jun; 29 (2):216-228 Epub 2016 Sept 07
    View PubMed
  24. Buhler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Durig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016 Mar 11; 6:e404.
    View PubMed
  25. Ailawadhi S, Advani P, Yang D, Ghosh R, Swaika A, Roy V, Foran J, Colon-Otero G, Chanan-Khan A. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. Cancer. 2016 Feb 15; 122: (4)618-25.
    View PubMed
  26. Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M, HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb; 17 (2):200-211 Epub 2015 Dec 05
    View PubMed
  27. Gaudette BT, Dwivedi B, Chitta KS, Poulain S, Powell D, Vertino P, Leleu X, Lonial S, Chanan-Khan AA, Kowalski J, Boise LH. Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrom macroglobulinemia. Oncogene. 2016 Jan 28; 35: (4)479-90.
    View PubMed
  28. Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Durig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016; 57: (6)1291-9.
    View PubMed
  29. Wang X, D'Arcy P, Caulfield TR, Paulus A, Chitta K, Mohanty C, Gullbo J, Chanan-Khan A, Linder S. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem Biol Drug Des. 2015 Nov; 86: (5)1036-48.
    View PubMed
  30. Voorhees PM, Orlowski RZ, Mulkey F, Watson P, Geyer S, Sanford BL, Bennett E, Chanan-Khan AA, Bloomfield CD, Larson RA. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol. 2015 Nov; 171 (3):373-7 Epub 2015 July 22
    View PubMed
  31. Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly K, Chanan-Khan A, Ailawadhi S. Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. Clin Lymphoma Myeloma Leuk. 2015 Oct; 15: (10)578-85.
    View PubMed
  32. Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood. 2015 Sep 10; 126: (11)1294-301.
    View PubMed
  33. Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer. 2015 Sep 1; 121: (17)2883-91.
    View PubMed
  34. Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14; 5:e338.
    View PubMed
  35. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81.
    View PubMed
  36. Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Advani P, Ailawadhi S, Sher T, Linder S, Chanan-Khan A. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstrom macroglobulinaemia tumour cells. Br J Haematol. 2015 May; 169: (3)377-90.
    View PubMed
  37. Shanafelt TD, Borah BJ, Finnes HD, Chaffee KG, Ding W, Leis JF, Chanan-Khan AA, Parikh SA, Slager SL, Kay NE, Call TG. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015 May; 11: (3)252-8.
    View PubMed
  38. Paulus A, Chitta KS, Wallace PK, Advani PP, Akhtar S, Kuranz-Blake M, Ailawadhi S, Chanan-Khan AA. Immunophenotyping of Waldenstroms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications. PLoS One. 2015; 10 (4):e0122338 Epub 2015 Apr 08
    View PubMed
  39. Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015; 56: (12)3320-8.
    View PubMed
  40. Chitta K, Paulus A, Caulfield TR, Akhtar S, Blake MK, Ailawadhi S, Knight J, Heckman MG, Pinkerton A, Chanan-Khan A. Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenstroms macroglobulinemia. Blood Cancer J. 2014 Nov 07; 4:e260.
    View PubMed
  41. Ailawadhi S, Swaika A, Razavi P, Yang D, Chanan-Khan A. Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups. Blood Cancer J. 2014 Sep 05; 4:e243.
    View PubMed
  42. Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol. 2014 Apr; 165: (1)78-88.
    View PubMed
  43. Chitta KS, Khan AN, Ersing N, Swaika A, Masood A, Paulus A, Qadeer A, Advani P, Sher T, Miller KC, Lee K, Chanan-Khan AA. Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells. Leuk Lymphoma. 2014 Mar; 55: (3)652-61.
    View PubMed
  44. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW, Lindor NM, McCormick JB, McWilliams RR, Parker AS, Riegert-Johnson DL, Rohrer Vitek CR, Schahl KA, Schultz C, Stewart K, Then GC, Wieben ED, Farrugia G. Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):15-23. Epub 2014 Mar 10.
    View PubMed
  45. Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T, Ziesmer S, Li Y, Johnson SH, Hart SN, Kocher JP, Vasmatzis G, Chanan-Kahn A, Gertz M, Fonseca R, Dogan A, Cerhan JR, Novak AJ. Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. Blood Cancer J. 2014 Feb 14; 4:e183.
    View PubMed
  46. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol. 2014 Feb; 164: (3)352-365.
    View PubMed
  47. Ailawadhi S, Kardosh A, Yang D, Cozen W, Patel G, Alamgir MA, Chanan-Khan AA. Outcome disparities among ethnic subgroups of Waldenstrom's macroglobulinemia: a population-based study. Oncology. 2014; 86(5-6):253-62. Epub 2014 Jun 04.
    View PubMed
  48. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19; 122: (26)4172-81.
    View PubMed
  49. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6. Epub 2013 May 14.
    View PubMed
  50. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6. Epub 2013 May 14.
    View PubMed
  51. Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013 Nov; 163(4):478-86. Epub 2013 Sep 25.
    View PubMed
  52. Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, Dispenzieri A, Lacy MQ. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013 Sep 06; 3:e143.
    View PubMed
  53. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88: (4)360-76.
    View PubMed
  54. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Blade J, Orlowski RZ, Shah JJ, International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr; 27(4):780-91. Epub 2012 Nov 21
    View PubMed
  55. Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA. Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstrom Macroglobulinemia 1. Leuk Lymphoma. 2013 Feb; 54: (2)387-96.
    View PubMed
  56. Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J. 2013; 3:e121. Epub 2013 Jun 28
    View PubMed
  57. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4; 120(14):2817-25. Epub 2012 Jul 25.
    View PubMed
  58. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foa R, Hellmann A, Dimopoulos M, Swern AS, Knight R. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients >/=65 years old with relapsed or refractory multiple myeloma. Int J Hematol. 2012 Aug; 96(2):254-62. Epub 2012 Jul 03.
    View PubMed
  59. Kasyapa CS, Sher T, Chanan-Khan AA. Multiple myeloma and immunomodulation: regulating the regulatory cells. Leuk Lymphoma. 2012 Jul; 53(7):1253-4. Epub 2012 Apr 03.
    View PubMed
  60. Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, Chanan-Khan A. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012 Jul; 158(1):91-8. Epub 2012 Apr 26.
    View PubMed
  61. Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012 Jul-Aug; 10: (4)155-9.
    View PubMed
  62. Blickwedehl J, Olejniczak S, Cummings R, Sarvaiya N, Mantilla A, Chanan-Khan A, Pandita TK, Schmidt M, Thompson CB, Bangia N. The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation. Mol Cancer Res. 2012 Jul; 10(7):937-44. Epub 2012 May 01.
    View PubMed
  63. Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A. Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Jun; 53(6):1174-82. Epub 2011 Dec 6
    View PubMed
  64. Rodgers GM 3rd, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB 3rd. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012 May; 10(5):628-53.
    View PubMed
  65. Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012 Apr 15; 18(8):2145-63. Epub 2012 Feb 10.
    View PubMed
  66. Smonskey MT, Block AW, Deeb G, Chanan-Khan AA, Bernstein ZP, Miller KC, Wallace PK, Starostik P. Monoallelic and biallelic deletions of 13q14.3 in chronic lymphocytic leukemia: FISH vs miRNA RT-qPCR detection. Am J Clin Pathol. 2012 Apr; 137(4):641-6.
    View PubMed
  67. Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012 Apr; 157: (1)59-66.
    View PubMed
  68. Wendtner CM, Hillmen P, Mahadevan D, Buhler A, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Mar; 53(3):417-23. Epub 2011 Nov 15.
    View PubMed
  69. Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011 Nov; 155: (4)457-67.
    View PubMed
  70. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, National Comprehensive Cancer Network. Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83.
    View PubMed
  71. Nair JR, Carlson LM, Koorella C, Rozanski CH, Byrne GE, Bergsagel PL, Shaughnessy JP, Boise LH, Chanan-Khan A, Lee KP. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol. 2011 Aug 1; 187(3):1243-53. Epub 2011 Jun 29.
    View PubMed
  72. Rozanski CH, Arens R, Carlson LM, Nair J, Boise LH, Chanan-Khan AA, Schoenberger SP, Lee KP. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med. 2011 Jul 4; 208(7):1435-46. Epub 2011 Jun 20.
    View PubMed
  73. Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol. 2011 Jul; 154(1):104-10. Epub 2011 May 09.
    View PubMed
  74. Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2011 Jun; 7: (6)765-74.
    View PubMed
  75. Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M, Anderson KC. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011 Jun; 153(6):729-40. Epub 2011 Apr 28.
    View PubMed
  76. Chanan-Khan A, Miller KC, Lawrence D, Padmanabhan S, Miller A, Hernandez-Illatazurri F, Czuczman MS, Wallace PK, Zeldis JB, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011 May 15; 117(10):2127-35. Epub 2010 Nov 29.
    View PubMed
  77. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S, International Myeloma. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 5; 117(18):4701-5. Epub 2011 Feb 03.
    View PubMed
  78. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79. Epub 2011 Jan 10.
    View PubMed
  79. Paulus A, Swaika A, Miller KC, Spangenthal EJ, Guo R, Vonfricken K, Lee K, Chanan-Khan AA. Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma. J Clin Oncol. 2011 Jan 20; 29: (3)e47-9.
    View PubMed
  80. Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A. Targeted treatment for chronic lymphocytic leukemia. Onco Targets Ther. 2011; 4:169-83.
    View PubMed
  81. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20; 28(33):4976-84. Epub 2010 Oct 18.
    View PubMed
  82. Chanan-Khan AA, Borrello I, Lee KP, Reece DE. Development of target-specific treatments in multiple myeloma. Br J Haematol. 2010 Oct; 151(1):3-15. Epub 2010 Jul 07.
    View PubMed
  83. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG, International Myeloma. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010 Oct; 24(10):1700-12. Epub 2010 Sep 02.
    View PubMed
  84. Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol. 2010 Aug; 150(4):418-27.
    View PubMed
  85. Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother. 2010 Aug; 59(8):1211-21. Epub 2010 Apr 27.
    View PubMed
  86. Miller KC, Musial L, Whitworth A, Chanan-Khan A. Management of patients with chronic lymphocytic leukemia treated with lenalidomide. Clin J Oncol Nurs. 2010 Aug; 14(4):491-9.
    View PubMed
  87. Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS, Anderson KC. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010 Aug; 150(4):438-45. Epub 2010 Jul 07.
    View PubMed
  88. Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein MA, Miller KC, Wood M, Sher T, Lee K, Chanan-Khan AA. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma. 2010 Jun; 51(6):1015-9.
    View PubMed
  89. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010 May 20; 28(15):2612-24. Epub 2010 Apr 12.
    View PubMed
  90. Ailawadhi S, Masood A, Sher T, Miller KC, Wood M, Lee K, Chanan-Khan A. Treatment options for multiple myeloma patients with high-risk disease. Med Oncol. 2010 Apr 14. [Epub ahead of print]
    View PubMed
  91. Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res. 2010; 29:8. Epub 2010 Jan 22.
    View PubMed
  92. Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, Miller A, Lawrence W, Bilgrami SA, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010 Jan; 51(1):85-8.
    View PubMed
  93. Chanan-Khan A, Musial L, Miller KC, Lawrence D, Whitworth A, Padmanabhan S, Wilding GE, Ailawadhi S, Patel M, Sher T, Bangia N, Zeldis JB, Bilgrami S, Czuczman MS, Wallace PK, Desai S, Lee K. Lenalidomide-Associated Tumor Flare Reaction in Patients with Chronic Lymphocytic Leukemia. Cancer. 2010.
  94. Ailawadhi S, Abdelhalim AN, Derby L, Mashtare TL, Miller KC, Wilding GE, Alberico RA, Gottlieb R, Klippenstein DL, Lee K, Chanan-Khan AA. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer. 2010 Jan 1; 116(1):84-92.
    View PubMed
  95. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):908-42.
  96. Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma. 2009 Jul; 50(7):1096-101.
    View PubMed
  97. Ghoshal P, Nganga A, Moran-Giuati J, Szafranek A, Johnson T, Bigelow A, Houde C, avet- Loiseau H, Smiraglia D, Chanan-Khan A, Coignet L. Loss of the SMRT/NCoR2 co-repressor correlates with JAG2 over-expression in multiple myeloma. Cancer Res. 2009; 69(10):4380-7.
  98. Patel MP, Chanan-Khan AA. The many lives of thalidomide. Leuk Lymphoma. 2009; 50(6):861-2.
  99. Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jaganath S. Phase III randomized study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma. 2009; 50(4):559-65.
  100. Sher T, Miller K, Lee K, Chanan-Khan A. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clin Lymphoma Myeloma. 2009; 9(4):328-30.
  101. Richardson PG, Xie W, Mitsiades CS, Chanan-Khan A, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter D, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi N, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato A. Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27(21):3518-25.
  102. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol. 2009; 21:516-523.
  103. O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan A, Seymour JF, Gribben J, Itri LM, Rai KR. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized phase 3 trial of fludarabine plus cyclophosphamide with our without oblimersen: the Oblimersen CLL Study Group. J Clin Oncol. 2009; 27(31):5208-12.
  104. Chanan-Khan AA, Sonneveld P, Harousseau JL, Richardson PG. Reply to C.A. Dasanu et al. J Clin Oncol. 2008 Oct 10; 26(29):4784-90.
  105. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Onc. 2008; 26(9):1544-52.
  106. Chanan-Khan AA, Whitworth A, Bangia N, Porter CW, Lee K. Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008; 26(9):4851-2.
  107. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008; 26:4784-90.
  108. Rodgers GM 3rd, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Djulbegovic B, Garst JL, Gilreath JA, Kraut EH, Lin WC, Matulonis U, Millenson M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein RS, Vig R: National Comprehensive Cancer Network. Cancer-and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008; 6:536-64.
  109. Manochakian R, Miller KC, Chanan-Khan AA. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist. 2007 Aug; 12: (8)978-90.
    View PubMed
  110. Moysich KB, Bonner MR, Beehler GP, Marshall JR, Menezes RJ, Baker JA, Weiss JR, Chanan-Khan A. Regular analgesic use and risk of multiple myeloma. Leuk Res. 2007; 31(4):547-51.
  111. Chanan-Khan A, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007; 109(6):2604-6.
  112. Manochakian R, Miller KC, Chanan-Khan A. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma. Clin Lymphoma Myeloma. 2007; 7(4):266-71.
  113. O'Brien S, Moore JO, Boyd TE, Larratt, LM, Skotnicki, A, Koziner, B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR, et al. Randomized Phase 3 Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 Antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2007; 25(9):1114-20.
  114. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yaholom J, Yunus F, National Comprehsnsive Cancer Network (NCCN). Multiple Myeloma: Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007; 5(3):118-147.
  115. Chanan-Khan A, Lee K. Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience. Clin Lymphoma. 2007; 48(6):1228-30.
  116. Reddy N, Karampelas I, Chanan-Khan A, Fenstermaker R, Padmanabhan S. Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage. Leu Lymph. 2007; 48(6):1228-30.
  117. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo D, Bennett MK, van Leeuwen, FW, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood. 2007; 110(9):3281-90.
  118. Chanan-Khan. New treatments for chronic lymphocytic leukemia. Curr Oncol Rep 9 (5) 353-360. 2007; 9(5):353-360.
  119. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Patin J, Yu Z, Olesnyckyj M, Zeldis J, Knight R. Randomized, Phase III, Placebo-Controlled Trial of Lenalidomide in Combination With High- Dose Dexamethasone for Relapsed or Primary Refractory Multiple Myeloma. N Engl J Med. 2007; 357(21):2133-42.
  120. O’Connor OA, Smith EA, Toner LE, Teruyda-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A. The combination of the proteasome inhibitor Bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res. 2006; 12(9):2902-11.
  121. Chanan-Khan A, Porter C. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol. 2006; 7:480-8.
  122. Chanan-Khan A, Miller KC. Supportive care in multiple myeloma. Clin Lymphoma Myeloma. 2006; 7(1):42-50.
  123. Chanan-Khan A, Miller, KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006; 24(34):5343-9.
  124. Miller KC, Padmanabhan S, DiMicelli L, DePaolo D, Landrigan B, Yu J, Doran, Marshal P, Chanan-Khan A. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma. 2006; 47(11):2339-43.
  125. Chanan-Khan A. Bcl-2 Antisense Therapy in B-cell Malignancies. Blood Reviews. 2005; 19(4):213-21.
  126. Czuczman MS, Fallon A, Stewart C, Donohue K, Blumerson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri FJ, Skippe M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005; 23(4):694-704.
  127. Scarpace S, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A, van Besien K, McCarthy Jr P. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005; 46(2):239-42.
  128. Chanan-Khan A, Holkova B, Goldenberg AS, Pavlic A, Demopoulos R, Takeshita K. Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: A Report of three cases. Leuk Lymphoma. 2005; 46(8):1189-93.
  129. Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczman MS. Results of a phase I clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment - requiring chronic lymphocytic leukemia (CLL). Blood. 2005; 106:3348-52.
  130. Rodgers GM, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Demetri GD, Djulbegovic B, Garst JL, Gore M, Kraut EH, Lin WC, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P. Cancer- and treatment-related anemia. J Nat Compr Canc Netw. 2005; 3(6):773-89.
  131. Chanan-Khan A. Bcl-2 antisense therapy in hematologic malignancies. Curr Opin Oncol. 2004 Nov; 16(6):581-5.
    View PubMed
  132. Chanan-Khan A, Islam T, Alam A, Miller KC, Gibbs J, Barcos M, Czuczman MS, Paplham P, Hahn T, McCarthy P. Long-term survival with allogeneic stem cell transplant following salvage therapy with anti-CD 52 monoclonal antibody (Campath®) in a patient with α/β hepatosplenic Tcell non-Hodgkin's lymphoma. Leukemia & Lymphoma. 2004; 45(8):1673-5.
  133. Chanan-Khan A, Sirinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. Journal of Supportive Oncology. 2004; 2(3):251-6.
  134. Srinivasan S, Takeshita K, Holkova B, Czuczman MS, Bernstein ZP, Miller K, Driscoll D, Chanan-Khan A. Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of highly active antiretroviral therapy (HAART). HIV Clinical Trials. 2004; 5(3):140-5.
  135. Chanan-Khan A, Czuczman MS. Bcl-2 Antisense Therapy in B-cell Malignant Proliferative Disorders. Current Treatment Options in Oncology. 2004; 5(4):261-7.
  136. Chanan-Khan A. Bcl-2 Antisense Therapy in the Treatment of Multiple Myeloma. Oncology. 2004; 18(13 suppl 10):21-4.
  137. Ramanarayanan J, Hernandez-Ilizaliturri F, Chanan-Khan A, Czuczman M. Pro-apoptotic therapy with the oligonucleotide Genasense(tm) (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumor activity of rituximab. British Journal ofHematology. 2004; 127(5):519-530.
  138. Hahn T, Rondeau C, Shaukat A, Jupudy V, Miller A, Alam AR, Baer MR, Bambach B, Bernstein Z, Chanan-Khan AA, Czuczman MS, Slack J, Wetzler M, Mookerjee BK, Silva J, McCarthy PL Jr. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant. 2003 Aug; 32(4):405-10.
    View PubMed
  139. Chanan-Khan A, Holkova B, Perle MA, Reich E, Wu CD, Takeshita K. T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. Haematologica. 2003; 88(05):ECR14.
  140. Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS, Bernstein ZP, Chanan-Khan AA, Becker JL, McCarthy PL. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant. 2003; 32(2):139-43.
  141. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, Muggia FM. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Annals of Oncology. 2003; 14(9):1430-7.
  142. Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer. 2002 Dec 15; 95(12):2555-61.
    View PubMed
  143. Ahmad I, Islam T, Chanan-Khan A, Hahn T, Wentling D, Becker J, McCarthy P, Alam A. Thalidomide as salvage therapy for VAD-refractory multiple myeloma patients prior to autologous PBSCT. Bone Marrow Transplant. 2002; 29:577-80.
  144. Bernstein ZP, Brooks SP, Chanan-Khan A, Gollnick SO, Gilbert MJ, Tomasi TB. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Restores Allostimulatory Function to Accessory Cells in Patients with AIDS. HIV Clinical Trials. 2002; 3(3):219-24.
  145. Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, Metselaar JM, Storm G, Chanan-Khan A, Liebes L, Muggia FM, Cohen R, Barenholz Y, Alving, CR. Role of complement activation in hypersensitivity reactions to Doxil and Hynic PEG Liposomes: Experimental and clinical studies J of Liposome Research. 2002; 12:165-72.
  146. Chanan-Khan A, Czuczman MS. Radioimmunotherapy in non-Hodgkin's lymphoma. Curr Opin Oncol. 2002; 14:484-9.
  147. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, Chanan-Khan A. Effect of highly active antiretroviral therapy on survival in patients with AIDSassociated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol. 2001; 19(18):3848-51.